CCMH
CYTK icon

Cornerstone Capital Management Holdings’s Cytokinetics CYTK Stock Holding History

Cornerstone Capital Management Holdings’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$125K Buy
15,411
+511
+3% +$5.8K ﹤0.01% 1153
2017
Q3 		$216K Buy
+14,900
New +$204K ﹤0.01% 1151
2017
Q1 		– Sell
-90,500
Closed -$1.1M – 1306
2016
Q4 		$1.1M Buy
+90,500
New +$960K 0.01% 933
2016
Q3 		– Sell
-8,600
Closed -$82K – 1384
2016
Q2 		$82K Sell
8,600
-29,452
-77% -$242K ﹤0.01% 1286
2016
Q1 		$269K Buy
38,052
+18,152
+91% +$133K ﹤0.01% 1160
2015
Q4 		$208K Buy
+19,900
New +$195K ﹤0.01% 1203
2015
Q3 		– Sell
-1,550
Closed -$10K – 1502
2015
Q2 		$10K Sell
1,550
-10,900
-88% -$71.5K ﹤0.01% 1396
2015
Q1 		$84K Sell
12,450
-48,400
-80% -$361K ﹤0.01% 1280
2014
Q4 		$487K Buy
60,850
+19,300
+46% +$82.8K 0.01% 979
2014
Q3 		$146K Buy
41,550
+29,000
+231% +$122K ﹤0.01% 1137
2014
Q2 		$59K Buy
12,550
+10,550
+528% +$64.4K ﹤0.01% 1231
2014
Q1 		$19K Buy
+2,000
New +$18.1K ﹤0.01% 1284

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LPU
Lansdowne Partners (UK) London, United Kingdom $2.43B AUM 103.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Cornerstone Capital Management Holdings's CYTK Position: Q4 2017 in Review

Cornerstone Capital Management Holdings increased its Cytokinetics (CYTK) stake by 3.4% in Q4 2017, buying an estimated $5.8K and bringing the position to 15,411 shares worth $125K. The position accounts for ﹤0.01% of the portfolio, ranked #1153.

Cornerstone Capital Management Holdings first reported a position in CYTK in Q1 2014 and has held it in 12 quarters since. The position peaked at $1.1M in Q4 2016. 134 funds tracked by Wall St. Rank hold CYTK as of Q4 2017.

  • Cornerstone Capital Management Holdings held 15,411 shares of Cytokinetics worth $125K as of Q4 2017.
  • Cornerstone Capital Management Holdings bought 511 Cytokinetics shares in Q4 2017, an estimated $5.8K.
  • Cytokinetics made up ﹤0.01% of Cornerstone Capital Management Holdings's portfolio in Q4 2017, its #1153 holding.
  • Cornerstone Capital Management Holdings first reported a position in Cytokinetics in Q1 2014 and has held it in 12 quarters since.
  • Cornerstone Capital Management Holdings's Cytokinetics position peaked at $1.1M in Q4 2016.
  • 134 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2017.

Based on Cornerstone Capital Management Holdings's 13F filing for Q4 2017, filed 14 Feb 2018.